Nearly Half of Patients Hit Major Weight Loss in Lilly's Retatrutide Trial

Eli Lilly's retatrutide helped 45% of trial participants lose at least 30% of their body weight over 80 weeks. That responder rate matters more than the average result because insurance companies use it to decide coverage. When roughly half a patient population hits a meaningful threshold—rather than just averaging improvement—payers view the drug as more cost-effective and are likelier to cover it.